CLINICAL TRIALS PROFILE FOR VYXEOS
✉ Email this page to a colleague
All Clinical Trials for Vyxeos
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02286726 ↗ | CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia | Completed | Celator Pharmaceuticals | Phase 2 | 2015-05-04 | This phase II trial studies the best dose and how well liposomal cytarabine-daunorubicin CPX-351 (CPX-351) works in treating patients with newly diagnosed acute myeloid leukemia and who are at risk for not responding well to treatment. Liposomal cytarabine-daunorubicin CPX-351 combines two chemotherapy drugs that are known to help each other work better, and may work to stop the growth of cancer cells by blocking the cells from dividing. |
| NCT02286726 ↗ | CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia | Completed | National Cancer Institute (NCI) | Phase 2 | 2015-05-04 | This phase II trial studies the best dose and how well liposomal cytarabine-daunorubicin CPX-351 (CPX-351) works in treating patients with newly diagnosed acute myeloid leukemia and who are at risk for not responding well to treatment. Liposomal cytarabine-daunorubicin CPX-351 combines two chemotherapy drugs that are known to help each other work better, and may work to stop the growth of cancer cells by blocking the cells from dividing. |
| NCT02286726 ↗ | CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia | Completed | M.D. Anderson Cancer Center | Phase 2 | 2015-05-04 | This phase II trial studies the best dose and how well liposomal cytarabine-daunorubicin CPX-351 (CPX-351) works in treating patients with newly diagnosed acute myeloid leukemia and who are at risk for not responding well to treatment. Liposomal cytarabine-daunorubicin CPX-351 combines two chemotherapy drugs that are known to help each other work better, and may work to stop the growth of cancer cells by blocking the cells from dividing. |
| NCT02533115 ↗ | EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML | Approved for marketing | Celator Pharmaceuticals | 1969-12-31 | This study is a Phase IV Expanded Access Protocol (EAP) of CPX-351 in patients with secondary acute myeloid leukemia who are suitable for treatment with intensive chemotherapy. | |
| NCT02533115 ↗ | EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML | Approved for marketing | Jazz Pharmaceuticals | 1969-12-31 | This study is a Phase IV Expanded Access Protocol (EAP) of CPX-351 in patients with secondary acute myeloid leukemia who are suitable for treatment with intensive chemotherapy. | |
| NCT02642965 ↗ | Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia | Active, not recruiting | National Cancer Institute (NCI) | Phase 1/Phase 2 | 2016-04-25 | This phase I/II trial studies the side effects and best dose of liposome-encapsulated daunorubicin-cytarabine when given with fludarabine phosphate, cytarabine, and filgrastim and to see how well they work in treating younger patients with acute myeloid leukemia that has come back after treatment (relapsed) or is not responding to treatment (is refractory). Liposome-encapsulated daunorubicin-cytarabine is made up of two chemotherapy drugs, cytarabine and daunorubicin hydrochloride, and works to stop cancer cell growth by blocking the cells from dividing. Drugs used in chemotherapy, such as fludarabine phosphate and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Filgrastim may increase the production of blood cells and may help the immune system recover from the side effects of chemotherapy. Giving liposome-encapsulated daunorubicin-cytarabine followed by fludarabine phosphate, cytarabine, and filgrastim may be a better treatment for patients with relapsed acute myeloid leukemia and may cause fewer side effects to the heart, a common effect of other chemotherapy treatments for acute myeloid leukemia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Vyxeos
Condition Name
Clinical Trial Locations for Vyxeos
Trials by Country
Clinical Trial Progress for Vyxeos
Clinical Trial Phase
Clinical Trial Sponsors for Vyxeos
Sponsor Name
